Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:ssptacrs1614

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS 3	AUG 06	FSTA enhanced with new thesaurus edition
NEWS 4	AUG 13	CA/CAplus enhanced with additional kind codes for granted patents
NEWS 5	AUG 20	CA/CAplus enhanced with CAS indexing in pre-1907 records
NEWS 6	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS 7	AUG 27	USPATOLD now available on STN
NEWS 8	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS 9	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS 10	SEP 13	FORIS renamed to SOFIS
NEWS 11	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS 12	SEP 17	CA/CAplus enhanced with printed CA page images from 1967-1998
NEWS 13	SEP 17	CAplus coverage extended to include traditional medicine patents
NEWS 14	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 15	OCT 02	CA/CAplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS 16	OCT 19	BEILSTEIN updated with new compounds
NEWS 17	NOV 15	Derwent Indian patent publication number format enhanced
NEWS 18	NOV 19	WPIX enhanced with XML display format
NEWS 19	NOV 30	ICSD reloaded with enhancements
NEWS 20	DEC 04	LINPADOCDB now available on STN
NEWS 21	DEC 14	BEILSTEIN pricing structure to change
NEWS 22	DEC 17	USPATOLD added to additional database clusters
NEWS 23	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS 24	DEC 17	DGENE now includes more than 10 million sequences
NEWS 25	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS 26	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS 27	DEC 17	CA/CAplus enhanced with new custom IPC display formats
NEWS 28	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS 29	JAN 02	STN pricing information for 2008 now available
NEWS 30	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances

NEWS EXPRESS 19 SEPTEMBER 2007: CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

```
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:53:56 ON 22 JAN 2008

=> file registy
'REGISTY' IS NOT A VALID FILE NAME
SESSION CONTINUES IN FILE 'HOME'
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available.  If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.

=> file registry
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.21       0.21

FILE 'REGISTRY' ENTERED AT 11:54:20 ON 22 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   21 JAN 2008  HIGHEST RN 1000370-19-3
DICTIONARY FILE UPDATES:  21 JAN 2008  HIGHEST RN 1000370-19-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10565453c.str
```



```
chain nodes :
13  14  15  16  23  24  25  26  27  28  29
ring nodes :
1  2  3  4  5  6  7  8  9  10  11  12  17  18  19  20  21  22
chain bonds :
1-13  4-7  10-14  14-15  14-23  15-16  16-17  20-29  22-24  24-25  25-26  27-28
ring bonds :
1-2  1-6  2-3  3-4  4-5  5-6  7-8  7-12  8-9  9-10  10-11  11-12  17-18  17-22
18-19  19-20  20-21  21-22
exact/norm bonds :
1-2  1-6  1-13  2-3  3-4  4-5  4-7  5-6  14-15  14-23  15-16  22-24  24-25
exact bonds :
10-14  16-17  20-29  25-26  27-28
normalized bonds :
7-8  7-12  8-9  9-10  10-11  11-12  17-18  17-22  18-19  19-20  20-21  21-22


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:Atom  8:Atom  9:Atom  10:Atom
11:Atom  12:Atom  13:CLASS  14:CLASS  15:CLASS  16:CLASS  17:Atom  18:Atom  19:Atom
 20:Atom  21:Atom  22:Atom  23:CLASS  24:CLASS  25:CLASS  26:CLASS  27:CLASS
28:CLASS  29:CLASS



L1      STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1              STR
```



Structure attributes must be viewed using STN Express query preparation.

```
=> s l1 fam ful
FULL SEARCH INITIATED 11:54:46 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -       10 TO ITERATE

100.0% PROCESSED       10 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

L2             0 SEA FAM FUL L1

=> s l1 sss ful
FULL SEARCH INITIATED 11:55:00 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -       34 TO ITERATE

100.0% PROCESSED       34 ITERATIONS                                5 ANSWERS
SEARCH TIME: 00.00.01

L3             5 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   248.01     248.22

FILE 'CAPLUS' ENTERED AT 11:55:10 ON 22 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
```

strictly prohibited.

FILE COVERS 1907 - 22 Jan 2008 VOL 148 ISS 4
FILE LAST UPDATED: 21 Jan 2008 (20080121/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l3
L4 2 L3

=> d 14

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:136573 CAPLUS
DN 142:212408
TI Combinations of a cathepsin K inhibitor and a bisphosphonate in the treatment of bone metastasis, tumor growth, tumor-induced bone loss, and bone loss diseases
IN Zimmermann, Johann; Goessl, Carsten
PA Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
SO PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005014006	A1	20050217	WO 2004-EP8107	20040720
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004262903	A1	20050217	AU 2004-262903	20040720
	AU 2004262903	B2	20070823		
	CA 2532948	A1	20050217	CA 2004-2532948	20040720
	EP 1651238	A1	20060503	EP 2004-741174	20040720
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
	CN 1826124	A	20060830	CN 2004-80021110	20040720
	BR 2004012769	A	20060926	BR 2004-12769	20040720
	JP 2006528151	T	20061214	JP 2006-520778	20040720
	IN 2006CN00226	A	20070629	IN 2006-CN226	20060118
	MX 2006PA00790	A	20060407	MX 2006-PA790	20060120
	NO 2006000851	A	20060421	NO 2006-851	20060221
	US 2006281714	A1	20061214	US 2006-565453	20060518
PRAI	US 2003-488925P	P	20030721		
	WO 2004-EP8107	W	20040720		

OS MARPAT 142:212408
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d l4 ibib abs 1-2

L4   ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2005:136573  CAPLUS
DOCUMENT NUMBER:          142:212408
TITLE:                    Combinations of a cathepsin K inhibitor and a
                          bisphosphonate in the treatment of bone metastasis,
                          tumor growth, tumor-induced bone loss, and bone loss
                          diseases
INVENTOR(S):              Zimmermann, Johann; Goessl, Carsten
PATENT ASSIGNEE(S):       Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
SOURCE:                   PCT Int. Appl., 45 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.          DATE
     --------------      ----   --------    -------------------      --------
     WO 2005014006        A1    20050217    WO 2004-EP8107           20040720
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
             SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
             SN, TD, TG
     AU 2004262903        A1    20050217    AU 2004-262903           20040720
     AU 2004262903        B2    20070823
     CA 2532948           A1    20050217    CA 2004-2532948          20040720
     EP 1651238           A1    20060503    EP 2004-741174           20040720
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR
     CN 1826124           A     20060830    CN 2004-80021110         20040720
     BR 2004012769        A     20060926    BR 2004-12769            20040720
     JP 2006528151        T     20061214    JP 2006-520778           20040720
     IN 2006CN00226       A     20070629    IN 2006-CN226            20060118
     MX 2006PA00790       A     20060407    MX 2006-PA790            20060120
     NO 2006000851        A     20060421    NO 2006-851              20060221
     US 2006281714        A1    20061214    US 2006-565453           20060518
PRIORITY APPLN. INFO.:                       US 2003-488925P     P    20030721
                                             WO 2004-EP8107      W    20040720

OTHER SOURCE(S):          MARPAT 142:212408
AB   The invention discloses pharmaceutical prepns. comprising certain types of
     bisphosphonates and certain types of Cathepsin K inhibitors, in particular
     for the prevention and treatment of bone metastases, tumor-induced
     hypercalcemia, tumor growth, tumor-induced bone loss and bone loss
     diseases such as osteoporosis or cancer therapy-induced bone loss.
REFERENCE COUNT:          4     THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
                                RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4   ANSWER 2 OF 2  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2003:202478  CAPLUS
DOCUMENT NUMBER:          138:221600
TITLE:                    Preparation of 2-cyano-4-aminopyrimidines as cathepsin
                          K inhibitors for the treatment of inflammations and
                          other diseases
```

INVENTOR(S): Altman, Eva; Hayakawa, Kenji; Iwasaki, Genji
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
SOURCE: PCT Int. Appl., 64 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003020278	A1	20030313	WO 2002-EP9661	20020829
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NO, NZ, OM, PH, PL, PT, RO, RU, SE, SG, SI, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR				
CA 2456127	A1	20030313	CA 2002-2456127	20020829
AU 2002333758	A1	20030318	AU 2002-333758	20020829
EP 1423121	A1	20040602	EP 2002-797650	20020829
EP 1423121	B1	20061115		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002012141	A	20040824	BR 2002-12141	20020829
CN 1549717	A	20041124	CN 2002-816963	20020829
JP 2005505550	T	20050224	JP 2003-524585	20020829
NZ 531287	A	20051223	NZ 2002-531287	20020829
AT 345136	T	20061215	AT 2002-797650	20020829
ES 2275946	T3	20070616	ES 2002-2797650	20020829
ZA 2004000677	A	20041208	ZA 2004-677	20040128
US 2004249153	A1	20041209	US 2004-487741	20040224
US 7112589	B2	20060926		
NO 2004000858	A	20040521	NO 2004-858	20040226
MX 2004PA01930	A	20040615	MX 2004-PA1930	20040227
IN 2004CN00443	A	20051223	IN 2004-CN443	20040301
US 2006074092	A1	20060406	US 2005-291007	20051130

PRIORITY APPLN. INFO.:			
	GB 2001-21024	A	20010830
	GB 2001-21026	A	20010830
	WO 2002-EP9661	W	20020829
	US 2004-487741	A3	20040224

OTHER SOURCE(S): MARPAT 138:221600
GI



I

AB The invention provides 2-cyano-4-amino-pyrimidines (shown as I; variables defined below; e.g. N-[[2-cyano-4-(2,2-dimethylpropylamino)pyrimidin-5-yl]methyl]-4-(4-methylpiperazin-1-ylmethyl)benzamide) or a pharmaceutically acceptable salt or ester thereof, which are inhibitors of cathepsin K and find use pharmaceutically for treatment of diseases and medical conditions in which cathepsin K is implicated, e.g. various disorders including inflammation, rheumatoid arthritis, osteoarthritis,

osteoporosis and tumors. Methods of preparation of I are also claimed. Two general procedures are given and characterization data for .apprx.100 examples of I are included. For example, N-[[2-cyano-4-(2,2-dimethylpropylamino)pyrimidin-5-yl]methyl]-2-(4-methoxyphenyl)acetamide was prepared starting from 5-(hydroxymethyl)uracil via intermediates 2,4-dichloro-5-chloromethylpyrimidine, (2-chloro-5-chloromethylpyrimidin-4-yl)(2,2-dimethylpropyl)amine, (5-azidomethyl-2-chloropyrimidin-4-yl)(2,2-dimethylpropyl)amine, (5-aminomethyl-2-chloropyrimidin-4-yl)(2,2-dimethylpropyl)amine and N-[[2-chloro-4-(2,2-dimethylpropylamino)pyrimidin-5-yl]methyl]-2-(4-methoxyphenyl)acetamide. For I: R is H, -R4, -OR4 or NR3R4 (R3 is H, lower alkyl or C3-C10 cycloalkyl; R4 is lower alkyl or C3-C10 cycloalkyl). R1 is -CO-NR5R6, -NH-CO-R5, -CH2-NH-C(O)-R5, -CO-R5, -S(O)-R5, -S(O)2-R5, -CH2-CO-R5 or -CH2-NR5R6 (R5 is aryl, aryl-lower alkyl, C3-C10cycloalkyl, C3-C10cycloalkyl-lower alkyl, heterocyclyl or heterocyclyl-lower alkyl; R6 is H, aryl, aryl-lower alkyl, aryl-lower-alkenyl, C3-C10cycloalkyl, C3-C10 cycloalkyl-lower alkyl, heterocyclyl or heterocyclyl-lower alkyl, or R5 and R6 together with the N atom to which they attached are joined to form an N-heterocyclyl group). R2 = H, or optionally substituted (lower alkyl, aryl, aryl-lower alkyl, C3-C110cycloalkyl, C3-C10cycloalkyl-lower alkyl, heterocyclyl or heterocyclyl-lower alkyl); addnl. details are included in the claims. N-[[2-cyano-4-(2,2-dimethylpropylamino)pyrimidin-5-yl]methyl]-4-(4-methylpiperazin-1-ylmethyl)benzamide and N-[[[2-cyano-4-(2,2-dimethylpropylamino)pyrimidin-5-yl]methyl]-4-[1-(2-methoxyethyl)piperidin-4-yl]methyl]benzamide have IC50s for inhibition of human cathepsin K of 3 nM and 1.5 nM resp.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	11.35	259.57
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.60	-1.60

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 12:00:23 ON 22 JAN 2008